Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2021

View Archived Issues

Benefit seen with tipifarnib in HRAS-mutant head and neck squamous cell carcinoma

Heartseed to initiate phase I/II LAPiS study of iPSC-derived cardiomyocyte spheroids

Data on weekly basal insulin LY-3209590 in patients with T2D presented

Vasomune provides preliminary phase I data for AV-001

GlaxoSmithKline initiates first-in-human study of GSK-4108771A

IMPACT Therapeutics synthesizes CHK1 inhibitors

Ono Pharmaceutical and Pharmaron Beijing patent DDR1 inhibitors

Chengdu Synowest Biotechnology discloses CDK inhibitors

Sunshine Lake Pharma presents new RET inhibitors

Enrollment ongoing in phase III study of LOXO-305 in MCL

New LECT2-targeting compounds identified by Alnylam Pharmaceuticals

Endocannabinoids act on astrocytes to prevent tremor

Safety and QoL data from phase III monarchE study of ET therapy with or without abemaciclib

DKN-01 demonstrates activity in gynecologic cancers with Wnt activating mutations

Japanese approval of Isturisa for endogenous Cushing's syndrome

RZ-358 shows promise for treating PGBH

Dual EBV oncoprotein targeting using upconversion nanomaterials for cancer monitoring and treatment

Multiple dosing of Lassa fever candidate LHF-535 well tolerated in healthy subjects

Depletion of DNA polymerase beta increases platinum sensitivity in epithelial ovarian cancers

FDA approves Myrbetriq tablets and granules for neurogenic detrusor overactivity in children

First-in-human data presented for SRP-9003 in patients with limb girdle muscular dystrophy type 2E

Sorrento reports further phase Ib data on COVI-MSC for COVID-19-induced ARDS

FDA accepts IND for phase Ib study of AT-100 for bronchopulmonary dysplasia

Chinese phase III trial of LY-03005 for major depressive disorder meets endpoints

Anaveon gains CTA clearance for phase I/II study of ANV-419 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...